| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.74 KB | License | |||
| 497.31 KB | Adobe PDF |
Advisor(s)
Abstract(s)
The most effective adjuvant therapy of non-muscle invasive bladder cancer (NMIBC) during the last 35 years has been the intravesical instillation with Bacillus Calmette-Guerin (BCG). However, despite its efficacy, approximately 30% of the patients present treatment failure and tumor may progress.
Description
Keywords
Citation
Lima, L., Ferreira, J. A., Medeiros, R., & Santos, L. (2015). A step towards personalized medicine: establishment of a pharmacogenomics profile of response to BCG intravesical immunotherapy in bladder cancer. In R. A. Silva, P. Baylina, F. Q. Vieira, C. Barrias, M. Rubim, T. Coelho, C. Prudêncio, & Â. Jesus (Eds.), II Congresso Internacional da Saúde Gaia Porto: Livro de Resumos (pp. 17-18). Escola Superior de Tecnologia da Saúde do Instituto Politécnico do Porto.
Publisher
ESTSP-IPP